Tourmaline Non Current Liabilities Total from 2010 to 2024

TRML Stock   24.44  1.22  4.75%   
Tourmaline Bio Non Current Liabilities Total yearly trend continues to be quite stable with very little volatility. The value of Non Current Liabilities Total is projected to decrease to about 238.4 K. From the period between 2010 and 2024, Tourmaline Bio, Non Current Liabilities Total regression line of its data series had standard deviation of  7,043,301 and standard deviation of  7,043,301. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
2010-12-31
Previous Quarter
251 K
Current Value
238.4 K
Quarterly Volatility
M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tourmaline Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tourmaline Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 31.4 K, Other Operating Expenses of 23.4 M or Research Development of 17.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.64. Tourmaline financial statements analysis is a perfect complement when working with Tourmaline Bio Valuation or Volatility modules.
  
Check out the analysis of Tourmaline Bio Correlation against competitors.
For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.

Latest Tourmaline Bio's Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of Tourmaline Bio over the last few years. It is Tourmaline Bio's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tourmaline Bio's overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Slightly volatile
   Non Current Liabilities Total   
       Timeline  

Tourmaline Non Current Liabilities Total Regression Statistics

Arithmetic Mean2,038,763
Geometric Mean161,989
Coefficient Of Variation345.47
Mean Deviation3,390,432
Median63,000
Standard Deviation7,043,301
Sample Variance49.6T
Range27.4M
R-Value0.33
Mean Square Error47.6T
R-Squared0.11
Significance0.23
Slope519,808
Total Sum of Squares694.5T

Tourmaline Non Current Liabilities Total History

2024238.4 K
2023251 K
202227.5 M
2021626 K
20201.4 M

About Tourmaline Bio Financial Statements

Tourmaline Bio investors utilize fundamental indicators, such as Non Current Liabilities Total, to predict how Tourmaline Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Non Current Liabilities Total251 K238.4 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Tourmaline Bio is a strong investment it is important to analyze Tourmaline Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tourmaline Bio's future performance. For an informed investment choice regarding Tourmaline Stock, refer to the following important reports:
Check out the analysis of Tourmaline Bio Correlation against competitors.
For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tourmaline Bio. If investors know Tourmaline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tourmaline Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.49)
Return On Assets
(0.24)
Return On Equity
(0.32)
The market value of Tourmaline Bio is measured differently than its book value, which is the value of Tourmaline that is recorded on the company's balance sheet. Investors also form their own opinion of Tourmaline Bio's value that differs from its market value or its book value, called intrinsic value, which is Tourmaline Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tourmaline Bio's market value can be influenced by many factors that don't directly affect Tourmaline Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tourmaline Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tourmaline Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tourmaline Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.